Adherence to evidence-based secondary prevention pharmacotherapy in patients after an acute coronary syndrome: A systematic review

Heart and Lung: Journal of Acute and Critical Care

Volumn 44, Issue 4, 2015, Pages 299-308

  Chen, Han Yang ^a   Saczynski, Jane S ^a,b   Lapane, Kate L ^a   Kiefe, Catarina I ^a   Goldberg, Robert J ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Acute coronary syndrome; Medication adherence; Pharmacotherapy; Secondary prevention; Systematic review

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ACUTE CORONARY SYNDROME; ARTICLE; CLINICAL TRIAL (TOPIC); DATA BASE; EVIDENCE BASED PRACTICE; HOSPITAL DISCHARGE; HUMAN; MEDICATION COMPLIANCE; PRIORITY JOURNAL; QUANTITATIVE STUDY; RISK FACTOR; SECONDARY PREVENTION; SYSTEMATIC REVIEW; ADULT; AGED; FACTUAL DATABASE; FEMALE; MALE; MIDDLE AGED;

ACUTE CORONARY SYNDROME; ADULT; AGED; CARDIOVASCULAR AGENTS; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PATIENT DISCHARGE; RISK FACTORS; SECONDARY PREVENTION;

EID: 84930819588     PISSN: 01479563     EISSN: 15273288     Source Type: Journal    
DOI: 10.1016/j.hrtlng.2015.02.004     Document Type: Article

References (52)

1. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129(3):e28-e292. 10.1161/01.cir.0000441139.02102.80.
2. Rockson S.G., deGoma E.M., Fonarow G.C. Reinforcing a continuum of care: in-hospital initiation of long-term secondary prevention following acute coronary syndromes. Cardiovasc Drugs Ther 2007, 21(5):375-388. 10.1007/s10557-007-6043-1.
3. O'Gara P.T., Kushner F.G., Ascheim D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JAm Coll Cardiol 2013, 61(4):e78-140. 10.1016/j.jacc.2012.11.019.
4. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
5. Fox K.A.A., Mehta S.R., Peters R., et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004, 110(10):1202-1208. 10.1161/01.CIR.0000140675.85342.1B.
6. Stenestrand U., Wallentin L. Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treatment following acute myocardial infarction and 1-year survival. JAm Med Assoc 2001, 285(4):430-436.
7. Hognestad A., Dickstein K., Myhre E., Snapinn S., Kjekshus J. Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure. Am J Cardiol 2004, 93(5):603-606. 10.1016/j.amjcard.2003.11.027.
8. Gustafsson I., Torp-Pedersen C., Køber L., Gustafsson F., Hildebrandt P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. JAm Coll Cardiol 1999, 34(1):83-89. 10.1016/S0735-1097(99)00146-1.
9. Torp-Pedersen C., Køber L. Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute m yocardial infarction. Lancet 1999, 354(9172):9-12. 10.1016/S0140-6736(98)09374-X.
10. Newby L.K., LaPointe N.M.A., Chen A.Y., et al. Long-term adherence to evidence-based secondary prevention therapies in coronary artery disease. Circulation 2006, 113(2):203-212. 10.1161/CIRCULATIONAHA.105.505636.
11. Naderi S.H., Bestwick J.P., Wald D.S. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376,162 patients. Am J Med 2012, 125(9):882-887.e1. 10.1016/j.amjmed.2011.12.013.
12. Ho P.M., Magid D.J., Shetterly S.M., et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008, 155(4):772-779. 10.1016/j.ahj.2007.12.011.
13. Sokol M.C., McGuigan K.A., Verbrugge R.R., Epstein R.S. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care 2005, 43(6):521-530.
14. Bitton A., Choudhry N.K., Matlin O.S., Swanton K., Shrank W.H. The impact of medication adherence on coronary artery disease costs and outcomes: a systematic review. Am J Med 2013, 126(4):357.e7-357.e27. 10.1016/j.amjmed.2012.09.004.
15. Cramer J.A., Roy A., Burrell A., et al. Medication compliance and persistence: terminology and definitions. Value Health 2008, 11(1):44-47. 10.1111/j.1524-4733.2007.00213.x.
16. Moher D., Liberati A., Tetzlaff J., Altman D.G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151(4):264-269. The PRISMA Group.
17. Gunnar R.M., Bourdillon P.D., Dixon D.W., et al. ACC/AHA guidelines for the early management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (subcommittee to develop guidelines for the early management of patients with acute myocardial infarction). Circulation 1990, 82:664-707. 10.1161/01.CIR.82.2.664.
18. Ho P.M., Bryson C.L., Rumsfeld J.S. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009, 119(23):3028-3035. 10.1161/CIRCULATIONAHA.108.768986.
19. Sabaté E. Adherence to Long-term Therapies: Evidence for Action 2003, World Health Organization, Geneva, Switzerland.
20. Downs S.H., Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. JEpidemiol Community Health 1998, 52(6):377-384.
21. Hajduk A.M., Kiefe C.I., Person S.D., Gore J.G., Saczynski J.S. Cognitive change in heart failure: a systematic review. Circ Cardiovasc Qual Outcomes 2013, 6(4):451-460. 10.1161/CIRCOUTCOMES.113.000121.
22. Pimentel C.B., Lapane K.L., Briesacher B.A. Medicare part D and long-term care: a systematic review of quantitative and qualitative evidence. Drugs Aging 2013, 30(9):701-720. 10.1007/s40266-013-0096-6.
23. Nordstrom B.L., Simeone J.C., Zhao Z., et al. Adherence and persistence with prasugrel following acute coronary syndrome with percutaneous coronary intervention. Am J Cardiovasc Drugs 2013, 13(4):263-271. 10.1007/s40256-013-0028-1.
24. Sanfelix-Gimeno G., Peiro S., Ferreros I., et al. Adherence to evidence-based therapies after acute coronary syndrome: a retrospective population-based cohort study linking hospital, outpatient, and pharmacy health information systems in Valencia, Spain. JManag Care Pharm 2013, 19(3):247-257.
25. Zhang Y., Baik S.H., Chang C.C., Kaplan C.M., Lave J.R. Disability, race/ethnicity, and medication adherence among Medicare myocardial infarction survivors. Am Heart J 2012, 164(3):425-433.e4. 10.1016/j.ahj.2012.05.021.
26. Danchin N., Neumann A., Tuppin P., et al. Impact of free universal medical coverage on medical care and outcomes in low-income patients hospitalized for acute myocardial infarction: an analysis from the French National Health Insurance system. Circ Qual Outcomes 2011, 4(6):619-625. 10.1161/CIRCOUTCOMES.111.961193.
27. Lai E.J., Grubisic M., Palepu A., Quan H., King K.M., Khan N.A. Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. BMC Cardiovasc Disord 2011, 11:56. 10.1186/1471-2261-11-56.
28. Allen LaPointe N.M., Ou F.S., Calvert S.B., et al. Association between patient beliefs and medication adherence following hospitalization for acute coronary syndrome. Am Heart J 2011, 161(5):855-863. 10.1016/j.ahj.2011.02.009.
29. Maio V., Marino M., Robeson M., Gagne J.J. Beta-blocker initiation and adherence after hospitalization for acute myocardial infarction. Eur J Cardiovasc Prev Rehabil 2011, 18(3):438-445. 10.1177/1741826710389401.
30. Belleudi V., Fusco D., Kirchmayer U., et al. Definition of patients treated with evidence based drugs in absence of prescribed daily doses: the example of acute myocardial infarction. Pharmacoepidemiol Drug Saf 2011, 20(2):169-176. 10.1002/pds.2079.
31. Zhu B., Zhao Z., McCollam P., et al. Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Curr Med Res Opin 2011, 27(3):633-641. 10.1185/03007995.2010.551657.
32. Tuppin P., Neumann A., Danchin N., et al. Evidence-based pharmacotherapy after myocardial infarction in France: adherence-associated factors and relationship with 30-month mortality and rehospitalization. Arch Cardiovasc Dis 2010, 103(6-7):363-375. 10.1016/j.acvd.2010.05.003.
33. Winkelmayer W.C., Levin R., Setoguchi S. Associations of kidney function with cardiovascular medication use after myocardial infarction. Clin J Am Soc Nephrol 2008, 3(5):1415-1422. 10.2215/CJN.02010408.
34. Chan V., Cooke C.E. Pharmacotherapy after myocardial infarction: disease management versus usual care. Am J Manag Care 2008, 14(6):352-358.
35. Rasmussen J.N., Chong A., Alter D.A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAm Med Assoc 2007, 297(2):177-186. 10.1001/jama.297.2.177.
36. Rieckmann N., Gerin W., Kronish I.M., et al. Course of depressive symptoms and medication adherence after acute coronary syndromes: an electronic medication monitoring study. JAm Coll Cardiol 2006, 48(11):2218-2222. 10.1016/j.jacc.2006.07.063.
37. Wei L., Flynn R., Murray G.D., MacDonald T.M. Use and adherence to beta-blockers for secondary prevention of myocardial infarction: who is not getting the treatment?. Pharmacoepidemiol Drug Saf 2004, 13(11):761-766. 10.1002/pds.963.
38. Simpson E., Beck C., Richard H., Eisenberg M.J., Pilote L. Drug prescriptions after acute myocardial infarction: dosage, compliance, and persistence. Am Heart J 2003, 145(3):438-444. 10.1067/mhj.2003.143.
39. Axon R.N., Williams M.V. Hospital readmission as an accountability measure. JAm Med Assoc 2011, 305(5):504-505. 10.1001/jama.2011.72.
40. Desai N.R., Choudhry N.K. Impediments to adherence to post myocardial infarction medications. Curr Cardiol Rep 2013, 15(1):322-326. 10.1007/s11886-012-0322-6.
41. Petrilla A.A., Benner J.S., Battleman D.S., Tierce J.C., Hazard E.H. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medications. Int J Clin Pract 2005, 59(12):1441-1451. 10.1111/j.1368-5031.2005.00704.x.
42. Zolnierek K.B.H., Dimatteo M.R. Physician communication and patient adherence to treatment: a meta-analysis. Med Care 2009, 47(8):826-834. 10.1097/MLR.0b013e31819a5acc.
43. Choudhry N.K., Shrank W.H. Four-dollar generics-increased accessibility, impaired quality assurance. NEngl J Med 2010, 363(20):1885-1887. 10.1056/NEJMp1006189.
44. Choudhry N.K., Lee J.L., Agnew-Blais J., Corcoran C., William H. Drug Company - sponsored patient assistance programs: a viable safety net?. Health Aff (Millwood) 2009, 28(3):827-834. 10.1377/hlthaff.28.3.827.Drug.
45. Osterberg L., Blaschke T. Adherence to medication. NEngl J Med 2005, 353(5):487-497. 10.1056/NEJMra050100.
46. Viana M., Laszczynska O., Mendes S., et al. Medication adherence to specific drug classes in chronic heart failure. JManag Care Pharm 2014, 20(10):1018-1026.
47. Gislason G.H., Rasmussen J.N., Abildstrom S.Z., et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007, 116:737-744. 10.1161/CIRCULATIONAHA.106.669101.
48. Waring M.E., McManus R.H., Saczynski J.S., et al. Transitions, risks, and actions in coronary Events-center for outcomes research and education (TRACE-CORE): design and rationale. Circ Cardiovasc Qual Outcomes 2012, 5(5):e44-50. 10.1161/CIRCOUTCOMES.112.965418.
49. Thomson S., Osborn R., Squires D., Jun M. International Profiles of Health Care Systems, 2013 2013, The Commonwealth Fund.
50. Cubanski J., Neuman P. Status report on Medicare Part D enrollment in 2006: analysis of plan-specific market share and coverage. Health Aff (Millwood) 2007, 26(1):w1-12. 10.1377/hlthaff.26.1.w1.
51. Goldman D.P., Joyce G.F., Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAm Med Assoc 2007, 298(1):61-69. 10.1001/jama.298.1.61.
52. Stuart B., Davidoff A., Erten M., et al. How Medicare Part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction. Health Serv Res 2013, 10.1111/1475-6773.12073.